Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.56 |
| ▸ | SMO | Q99835 | 4/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
| ▸ | RBP4 | P02753 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2940020 | 0.93 | IGF1R (0.57) | IGF1RSMOALDH1A1HTTCTSS | |
| SCHEMBL2940368 | 0.91 | IGF1R (0.55) | IGF1RSMOHTTLMNAMAPK1 | |
| SCHEMBL2934009 | 0.91 | IGF1R (0.57) | IGF1RSMOALDH1A1HTTLMNA | |
| SCHEMBL2937516 | 0.86 | IGF1R (0.63) | IGF1RSMOHTTCTSSLMNA | |
| SCHEMBL2939630 | 0.86 | IGF1R (0.40) | IGF1RSMOABL1KIT | |
| SCHEMBL2940106 | 0.86 | EPHX2 (0.40) | IGF1RABL1ALDH1A1TP53MDM2 | |
| SCHEMBL2937464 | 0.86 | IGF1R (0.62) | IGF1RSMOCTSS | |
| SCHEMBL2936962 | 0.84 | IGF1R (0.60) | IGF1RSMOCTSS | |
| SCHEMBL2938933 | 0.84 | IGF1R (0.60) | IGF1RSMO | |
| SCHEMBL2939416 | 0.84 | IGF1R (0.37) | IGF1RALDH1A1HTTHRH4CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825115-B2 | Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-11-02 | — | — | US | disclosed |
| EP-1599464-B1 | NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2010-09-22 | — | — | EP | disclosed |
| US-20080108654-A1 | Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-05-08 | — | — | US | disclosed |
| US-7354933-B2 | Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate | AVENTIS PHARMA SA (FR) | 2008-04-08 | — | — | US | disclosed |
| US-20040248884-A1 | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108654-A1 | Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors | PRKG1, PRKACA, CMPK1 | IGF1R 1595/4885SMO 2187/4885ABL1 776/4885 |
| US-20040248884-A1 | Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors | PRKG1, PRKACA, PRKCA | IGF1R 962/4885SMO 2697/4885ABL1 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.